您的当前位置:首页 > 行业数据 > HTD1801与Lanifibranor、Resmetirom(Rezdiffra)的II期临床试验结果对比
图片属性
图片格式:PNG 图片大小:403KB 图片尺寸:2168*1591
同报告图片
 / 4
HTD1801与Lanifibranor、Resmetirom(Rezdiffra)的II期临床试验结果对比_第1页
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
HTD1801与Lanifibranor、Resmetirom(Rezdiffra)的II期临床试验结果对比_第2页
HTD1801与Lanifibranor、Resmetirom(Rezdiffra)的II期临床试验结果对比_第3页
HTD1801与Lanifibranor、Resmetirom(Rezdiffra)的II期临床试验结果对比_第4页
HTD1801与Lanifibranor、Resmetirom(Rezdiffra)的II期临床试验结果对比_第5页
所属报告: 君圣泰医药~B-港股公司研究报告-HTD1801发力代谢疾病市场-250527(26页).pdf
打包全文图表

相关数据

客服
商务合作
小程序
服务号
折叠